Acrodermatitis chronica atrophicans historical perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Raviteja Guddeti, M.B.B.S. [3]
|
Acrodermatitis chronica atrophicans Microchapters |
|
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans historical perspective On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans historical perspective |
|
FDA on Acrodermatitis chronica atrophicans historical perspective |
|
CDC on Acrodermatitis chronica atrophicans historical perspective |
|
Acrodermatitis chronica atrophicans historical perspective in the news |
|
Blogs on Acrodermatitis chronica atrophicans historical perspective |
|
Risk calculators and risk factors for Acrodermatitis chronica atrophicans historical perspective |
Overview
In 1883, acrodermatitis chronica atrophicans was described for the first time by a German physician named Alfred Buchwald. Later in 1902 Herxheimer and Hartmann described it as a "tissue paper" like cutaneous atrophy and there were first physicians that came up with acrodermatitis chronica atrophicans's name. They described the biphasic manner of this disease by demonstrating both inflammatory and atrophic phases of it. In 1950s the possibility of human to human transmission was discussed.For the first time in 1984, borrelia was discovered as the responsible etiology of acrodermatitis chronica atrophicans.
Historical Perspective
- In 1883, acrodermatitis chronica atrophicans was described for the first time by a German physician named Alfred Buchwald.
- In 1895 Pick reported the inflammatory phase as a new disease and he named it eythromelie.[1]
- Later in 1902 Herxheimer and Hartmann described it as a "tissue paper" like cutaneous atrophy. They were the first physicians that described both inflammatory and atrophic phases as different phases of a single disease. They named it acrodermatitis chronica atrophicans.[1]
- In 1946 penicillin has been recommended as an effective treatment.
- The possibility of human to human transmission was first discovered in 1950s.
- For the first time in 1984, borrelia was discovered as the responsible etiology of acrodermatitis chronica atrophicans. Before that conditions such as elastin weakness, trophic disturbances or vascular diseases were believed to be the etiologies of acrodermatitis chronica atrophicans. [2][1]
- First case of acrodermatitis chronica atrophicans in North America was reported in 1895.[3]
References
- ↑ 1.0 1.1 1.2 Asbrink E (1993). "Acrodermatitis chronica atrophicans". Clin Dermatol. 11 (3): 369–75. doi:10.1016/0738-081x(93)90092-q. PMID 8221518.
- ↑ Picken RN, Strle F, Picken MM, Ruzic-Sabljic E, Maraspin V, Lotric-Furlan S; et al. (1998). "Identification of three species of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto, B. garinii, and B. afzelii) among isolates from acrodermatitis chronica atrophicans lesions". J Invest Dermatol. 110 (3): 211–4. doi:10.1046/j.1523-1747.1998.00130.x. PMID 9506437.
- ↑ Scott JD (2020). "Presentation of Acrodermatitis Chronica Atrophicans Rashes on Lyme Disease Patients in Canada". Healthcare (Basel). 8 (2). doi:10.3390/healthcare8020157. PMC 7349802 Check
|pmc=value (help). PMID 32512846 Check|pmid=value (help).